Answer

No, you should not take St. John's Wort while taking Alpelisib. This combination is considered a critical interaction that can significantly reduce the efficacy of your cancer treatment.

Evidence Assessment

Quality Score: 90 (Tier A) The evidence for this interaction is based on established pharmacokinetic principles regarding the induction of cytochrome P450 enzymes and is verified by the DDInter 2.0 database.

Clinical Evidence

Alpelisib is a PI3K inhibitor used in the treatment of certain breast cancers. St. John's Wort is a potent inducer of the CYP3A4 enzyme and the P-glycoprotein (P-gp) efflux transporter. Because Alpelisib is metabolized primarily by the CYP3A4 pathway, the introduction of St. John's Wort leads to an increase in the rate of drug metabolism.

The clinical result of this interaction is a significant reduction in the plasma concentration (AUC) of Alpelisib. When the concentration of a targeted oncology medication falls below the therapeutic threshold, the drug may fail to inhibit the PI3K pathway effectively, potentially leading to disease progression or a lack of response to chemotherapy.

Practical Guidance

• Population: This interaction is critical for patients with advanced breast cancer undergoing targeted therapy.
• Management: If a patient is currently taking St. John's Wort, it must be discontinued before starting Alpelisib. Due to the long-lasting effects of enzyme induction, a washout period may be necessary before Alpelisib can reach stable therapeutic levels.
• Alternatives: Patients seeking mood support should discuss non-inducing alternatives with their oncologist, as many herbal supplements can interfere with chemotherapy.

Safety & Interactions

Verdict: NO (Contraindicated)

• Drug Class/Mechanism: CYP3A4 Inducer (St. John's Wort) $\rightarrow$ PI3K Inhibitor (Alpelisib). The supplement accelerates the breakdown of the medication via the liver's cytochrome P450 system.
• Clinical Management: Immediate cessation of St. John's Wort is required. Healthcare providers must monitor for signs of decreased drug efficacy if this combination has occurred.
• High-Risk Populations: Patients with hepatic impairment may experience unpredictable metabolic rates, further complicating the interaction.
• Warning: Combining potent enzyme inducers with targeted oncology agents can lead to treatment failure. Always consult your oncologist before starting any supplement.